2026-10-14T07:44:10Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34047983 2026-10-01T17:28:54Z category_7 category_12 category_21 category_873 category_45 category_734 category_106 portal_5 item_type_3 month_year_10_2026

<p>The characteristics of the included studies.</p> Nanthida Phattraprayoon (12342384) Nut Koonrungsesomboon (5751497) Mingkwan Na Takuathung (12283012) Medicine Cell Biology Biotechnology Chemical Sciences not elsewhere classified Sociology Biological Sciences not elsewhere classified Science Policy randomized controlled trials commonly affects near calculate mean differences ci [&# 8722 salbutamol significantly decreased greater disease severity comprising seventeen rcts improve respiratory outcomes analysis </ p 004 ), duration 003 ), duration analysis involving 1 respiratory support 12 ), 001 ), subgroup analysis analysis showed analysis aimed &# 8722 nebulized salbutamol systematic review significant effect significant decrease searched pubmed potential benefits oxygen requirement five studies effects model cochrane library clinical score <div><p>Transient tachypnea of the newborn (TTN) commonly affects near- and full-term infants and often requires respiratory support. The use of nebulized salbutamol to improve respiratory outcomes has been of interest, though its clinical efficacy remains controversial. This systematic review and meta-analysis aimed to evaluate whether nebulized salbutamol improves clinical outcomes in affected infants. We searched PubMed, Scopus, Embase, and the Cochrane Library for randomized controlled trials (RCTs) evaluating the efficacy of nebulized salbutamol in infants with TTN. We used a random-effects model to calculate mean differences (MDs) with 95% confidence intervals (CIs). Twenty-five studies were included in the systematic review, comprising seventeen RCTs for meta-analysis involving 1,317 infants. The analysis showed that salbutamol significantly decreased the duration of respiratory support (MD: −14.85 hours; 95% CI [−25.05, −4.65]; p = 0.004), duration of continuous positive airway pressure (MD: −18.19 hours; 95% CI [−30.03, −6.35]; p = 0.003), duration of oxygen requirement (MD: −24.57 hours; 95% CI [−35.03, −14.10]; p < 0.001), and length of hospitalization (MD: −1.17 days; 95% CI [−1.69, −0.65]; p < 0.001). However, there was no significant decrease in duration of tachypnea (MD: −9.93 hours; 95% CI [−25.42, 5.56]; p = 0.21) or duration of neonatal intensive care unit stay (MD: −0.84 days; 95% CI [−2.62, 0.94]; p = 0.36). Subgroup analysis for respiratory support duration showed no significant effect in infants with clinical score of TTN < 5 (MD: −10.88 hours; 95% CI [−24.48, 2.73]; p = 0.12), while the certainty of evidence for all outcomes was low to very low. Nebulized salbutamol may improve clinical outcomes relevant to the evolution of the disease in TTN infants, with potential benefits in certain subgroups such as those with greater disease severity, though the available evidence is of low to very low certainty. Therefore, our confidence in its efficacy in treating TTN remains limited.</p></div> 2026-10-01T17:28:39Z Dataset Dataset 10.1371/journal.pone.0359663.t001 https://figshare.com/articles/dataset/_p_The_characteristics_of_the_included_studies_p_/34047983 CC BY 4.0